CAP President Donald S. Karcher, MD, FCAP, discusses the upcoming rule on laboratory-developed tests. “We believe the rule, as written, would significantly burden clinical laboratories, making it very difficult and unacceptably costly for these laboratories to continue to develop much-needed and innovative LDTs, resulting in patients being deprived of these life-saving tests,” said Dr. Karcher.
For the full article click here: Waiting on OIRA for final LDT rule